Literature DB >> 24940339

Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis.

R A Ngala1, K Fianko2.   

Abstract

BACKGROUND: Diet and genetic predisposition significantly affect lipid metabolism in the individual. This metabolic effect is further challenged in patients infected with HIV and on HAART. The prolonged use of HAART is associated with lipodystrophy, dyslipidemia, and insulin resistance.
OBJECTIVE: To determine the prevalence of lipid dysregulation and dysglycaemia in HIV infected patients on HAART in the Kumasi metropolis.
METHODS: This cross sectional study was conducted between October 2009 and June 2010, and 305 HIV-infected patients consisting of 164 patients on HAART for at least six months and 141 HAART-naive patients constituted HIV-positive patients, not on HAART and whose CD4 were not below 320 cell/ml as the control. Data was analyzed using Graph Pad Prism (version 5.0). Unpaired t-test, linear and multivariate regression analyses, was used to predict glucose level from the various parameters. Anthropometric parameters consisting of body weight, waist and hip circumferences, height, bicep and triceps skin fold were measured with a pair of calipers. Lipid profile and fasting blood glucose were determined by enzymatic methods. CD4 counts and hemoglobin were determined.
RESULTS: Fasting plasma, glucose (3.81±0.08mmol/l, 4.48±0.17mmol/l), total cholesterol (3.05± 0.0 8mmol/l, 4.54±0.08mmol/l) LDL (2.24±0.07mmol/l, 2.87±0.07mmol/l) and HDL (0.85±0.04mmol/l, 0.97±0.03mmol/l) between the control and case respectively were significantly raised (P< 0.001), though within the physiological range. The significantly increased hip and waist circumferences, waist-to-hip ratio (0.85±0.22, 0.88±0.01) of the control and case correlated with lipodystrophy.
CONCLUSION: HAART was associated with lipodystrohy and, the risk of developing type II diabetes among the HAART experienced group was 5 times higher than the HAART naive group.

Entities:  

Keywords:  HAART; HIV; Hypertriglyceridemia; non-nucleoside reverse transcriptase inhibitor; nucleoside reverse transcriptase inhibitor

Mesh:

Substances:

Year:  2013        PMID: 24940339      PMCID: PMC4056472          DOI: 10.4314/ahs.v13i4.35

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  42 in total

1.  Treating antiretroviral-induced dyslipidemia in HIV-infected adults.

Authors:  Kristine A Scordo
Journal:  Nurse Pract       Date:  2010-07

2.  Low density lipoprotein apolipoprotein B metabolism in treatment-naive HIV patients and patients on antiretroviral therapy.

Authors:  A Margot Umpleby; Satyajit Das; Michael Stolinski; Fariba Shojaee-Moradie; Nicola C Jackson; William Jefferson; Nicky Crabtree; Peter Nightingale; Mohsen Shahmanesh
Journal:  Antivir Ther       Date:  2005

Review 3.  Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis.

Authors:  Stacy D Fisher; Tracie L Miller; Steven E Lipshultz
Journal:  Atherosclerosis       Date:  2005-11-16       Impact factor: 5.162

4.  A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

Authors:  T Saint-Marc; M Partisani; I Poizot-Martin; F Bruno; O Rouviere; J M Lang; J A Gastaut; J L Touraine
Journal:  AIDS       Date:  1999-09-10       Impact factor: 4.177

5.  Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database.

Authors:  K V Heath; R S Hogg; K J Chan; M Harris; V Montessori; M V O'Shaughnessy; J S Montanera
Journal:  AIDS       Date:  2001-01-26       Impact factor: 4.177

6.  Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.

Authors:  Mustafa A Noor; Tara Seneviratne; Francesca T Aweeka; Joan C Lo; Jean-Marc Schwarz; Kathleen Mulligan; Morris Schambelan; Carl Grunfeld
Journal:  AIDS       Date:  2002-03-29       Impact factor: 4.177

7.  Morbidity and mortality in HIV-infected individuals - a shift towards comorbidities.

Authors:  Manuel Battegay; Luigia Elzi
Journal:  Swiss Med Wkly       Date:  2009-10-03       Impact factor: 2.193

8.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

Authors:  A Carr; K Samaras; S Burton; M Law; J Freund; D J Chisholm; D A Cooper
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

Review 9.  Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy.

Authors:  Eric Bonnet; Annelise Genoux; Jacques Bernard; Josette Fauvel; Patrice Massip; Bertrand Perret
Journal:  Clin Chem Lab Med       Date:  2007       Impact factor: 3.694

10.  Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men.

Authors:  J M Chan; E B Rimm; G A Colditz; M J Stampfer; W C Willett
Journal:  Diabetes Care       Date:  1994-09       Impact factor: 19.112

View more
  6 in total

Review 1.  Metabolic clinic for individuals with HIV/AIDS: a commitment and vision to the future of HIV services.

Authors:  Mohamed H Ahmed; Clare Woodward; Dushyant Mital
Journal:  Cardiovasc Endocrinol       Date:  2017-08-18

Review 2.  Managing dyslipidemia in HIV/AIDS patients: challenges and solutions.

Authors:  Nazik Elmalaika Os Husain; Mohamed H Ahmed
Journal:  HIV AIDS (Auckl)       Date:  2014-12-17

Review 3.  Diabetes, metabolic syndrome and dyslipidemia in people living with HIV in Africa: re-emerging challenges not to be forgotten.

Authors:  Nazik Elmalaika Husain; Sufian K Noor; Wadie M Elmadhoun; Ahmed O Almobarak; Heitham Awadalla; Clare L Woodward; Dushyant Mital; Mohamed H Ahmed
Journal:  HIV AIDS (Auckl)       Date:  2017-11-08

4.  The association between antiretroviral therapy and selected cardiovascular disease risk factors in sub-Saharan Africa: A systematic review and meta-analysis.

Authors:  Christian Akem Dimala; Hannah Blencowe; Simeon Pierre Choukem
Journal:  PLoS One       Date:  2018-07-30       Impact factor: 3.240

5.  Association of single nucleotide polymorphisms with dyslipidemia in antiretroviral exposed HIV patients in a Ghanaian population: A case-control study.

Authors:  Christian Obirikorang; Emmanuel Acheampong; Lawrence Quaye; Joseph Yorke; Ernestine Kubi Amos-Abanyie; Priscilla Abena Akyaw; Enoch Odame Anto; Simon Bannison Bani; Evans Adu Asamoah; Emmanuella Nsenbah Batu
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

6.  Single nucleotide polymorphisms in LCAT may contribute to dyslipidaemia in HIV-infected individuals on HAART in a Ghanaian population.

Authors:  Simon Bannison Bani; Kwabena Owusu Danquah; Christian Obirikorang; William K B A Owiredu; Lawrence Quaye; Edmund Muonir Der; Emmanuel Acheampong; Yussif Adams; Peter Paul M Dapare; Moses Banyeh; Enoch Odame Anto; Samuel Asamoah Sakyi
Journal:  Sci Rep       Date:  2020-11-10       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.